Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study

Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity. Obje...

Full description

Saved in:
Bibliographic Details
Published in:Colombia médica (Cali, Colombia) Colombia), 2021-02, Vol.52 (1), p.e2034542
Main Authors: Linares Ballesteros, Adriana, Sanguino Lobo, Roy, Villada Valencia, Juan Camilo, Arévalo Leal, Oscar, Plazas Hernández, Diana Constanza, Aponte Barrios, Nelson, Perdomo Ramírez, Iván
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity. Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy. Methods: A prospective descriptive study of patients >1 y and 150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity. Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction.
ISSN:0120-8322
1657-9534
DOI:10.25100/cm.v52i1.4542